Trevogrumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Obesity. According to GlobalData, Phase II drugs for Obesity have a 29% phase transition success ...

Emma Raducanu suffered a chastening 6-1 6-0 defeat by Iga Swiatek in the Australian Open third round on Saturday but the Briton said she was grateful to be fully fit and playing at a high level ...

With a market cap of $77.3 billion, Regeneron Pharmaceuticals, Inc. (REGN) is a leading biotechnology company dedicated to discovering, developing, and commercializing innovative treatments for a ...

If that doesn't merit national recognition, what does? Listen to Story Vidwan Sridhar Jain, known as the 'dancing prince of Mysuru', teaches dance for free. He founded Sri Nimishambha School of Dance ...

Regeneron Pharmaceuticals Inc.'s executives and board members overstated its key eye treatment’s average selling price, prompting a Department of Justice enforcement action and exposing the drugmaker ...

© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

Your biospecimen will be sent to the Regeneron Genetics Center for genetic sequencing, then stored for future analysis. With something as sacred as your genetic material in its hands, Truveta and ...

IT and Industries Minister D. Sridhar Babu met Union Minister for Electronics and Information Technology Ashwini Vaishnaw and sought Central support for advancing the State’s role in the country ...

Anup Sridhar will be taking over from Mulyo Handoyo, who stepped down from the position in the middle of last year (HT) The development took place in December when the Singapore Badminton ...

Investing.com -- UBS has downgraded Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to "Neutral" from "Buy" given uncertainty around its key Eylea franchise. Brokerage slashed price target to $738 ...

Regeneron stock has trended bearishly since August, but growth in LIBTAYO and DUPIXENT offers a promising outlook, prompting a BUY rating. EYLEA HD's success mitigates biosimilar competition ...

Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ...